# EDGAR Filing Document

**Accession Number:** 0001533998
**File Stem:** 0001104659-23-007572
**Filing Date:** 2023-1
**Character Count:** 23550
**Document Hash:** 17e8d21cb09c8a0840087a84eac1d7ca
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-007572.hdr.sgml**: 20230127

**ACCESSION NUMBER**: 0001104659-23-007572

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20230123

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230127

**DATE AS OF CHANGE**: 20230127

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** DarioHealth Corp.
- **CENTRAL INDEX KEY:** 0001533998
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **IRS NUMBER:** 452973162
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37704
- **FILM NUMBER:** 23563857

**BUSINESS ADDRESS:**
- **STREET 1:** 18 W 18TH ST., 5TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10011
- **BUSINESS PHONE:** 646.665.4667

**MAIL ADDRESS:**
- **STREET 1:** 18 W 18TH ST., 5TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10011

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** LabStyle Innovations Corp.
- **DATE OF NAME CHANGE:** 20111101

?xml version="1.0" encoding="utf-8"?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of Earliest Event Reported): January 23, 2023

**DARIOHEALTH CORP.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-37704** | **45-2973162** |
| (State or other jurisdiction <br> of incorporation) | (Commission<br> File Number) | (IRS Employer<br> Identification No.) |

---

**18 W. 18th St, 5th Floor**

**New York** **, New York 10019**

(Address of Principal Executive Offices)

**972- 4-770-4055** 

(Issuer's telephone number)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:

◻ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

◻ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

◻ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

◻ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br> Symbol(s)** | **Name of exchange on which <br> registered** |
| Common Stock, par value $0.0001 per share | DRIO | The Nasdaq Capital Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

---

| | |
|:---|:---|
| **Item 5.02** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.** |

---

On January 23, 2023, DarioHealth Corp. (the "Company"), through its wholly owned subsidiary Labstyle Innovation Ltd., executed a Termination of Employment and Separation Agreement (the "Agreement") with Dror Bacher, the Company's Chief Operating Officer, pursuant to which Mr. Bacher's position as Chief Operating Officer was terminated with immediate effect.

Pursuant to the terms of the Agreement, the Company agreed to retain Mr. Bacher as a member of its advisory board. The Company also agreed to pay Mr. Bacher, in lieu of his notice period and accrued vacation, a reduced monthly salary of 42,137 NIS ($12,504) for the period from February 1, 2023 through May 31, 2025. In addition, the Company agreed, subject to the approval of the Company's Compensation Committee, to issue Mr. Bacher 75,000 shares of restricted stock which shall vest on a quarterly basis from the date of grant through December 31, 2024.

The foregoing description of the terms of the Agreement are not intended to be complete and is qualified in its entirety by reference to the Agreement, a copy of which is attached hereto as Exhibit 10.1 and incorporated herein by reference.

---

| | |
|:---|:---|
| **Item 9.01** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Financial Statements and Exhibits.** |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Exhibits

---

| | |
|:---|:---|
| [10.1](tm234507d1_ex10-1.htm) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Termination of Employment and Separation Agreement dated January 23, 2023 by and between Dror Bacher and Labstyle Innovation Ltd.](tm234507d1_ex10-1.htm) |
| 104 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Dated: January 27, 2023 | **DARIOHEALTH CORP.** | **DARIOHEALTH CORP.** |
|  | By: | /s/ Zvi Ben David |
|  | Name: | Zvi Ben-David |
|  | Title: | Chief Financial Officer, Treasurer and Secretary |

---

## Exhibit 10.1

**Exhibit 10.1**

**<u>Termination of Employment and Separation Agreement</u>**

**Between**: **LabStyle Innovation Ltd**., No. 514668466 (the "**Company**")

**And**: **Dror Bacher,** I.D. No. 32068470 (the "**Employee**")

---

| | |
|:---|:---|
| **WHEREAS:** | The Employee is employed by the Company as of November 1, 2013 (the "**Commencement Date**"), all in accordance with the provisions of the employment agreement dated September 22, 2013, as was amended from time to time (the "**Employment Agreement**"); and |

---

---

| | |
|:---|:---|
| **WHEREAS:** | to this date, the Employee acts in the position of Chief Operation Officer (the **"Position**"); and |

---

---

| | |
|:---|:---|
| **WHEREAS:** | The Employee and the Company have mutually agreed on termination of Employee's employment with the Company; and |

---

---

| | |
|:---|:---|
| **WHEREAS:** | Following negotiations, the Company and the Employee (the "**Parties**") reached an agreement with respect to Employee's termination package, and they wish to put in writing their mutual obligations, as detailed in this termination and separation agreement (the "**Agreement**"). |

---

**NOW, THEREFORE, the parties hereby agree as follows:**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.  **<u>Termination of the Position</u>:** as of the date of execution of this Agreement by the Parties
(the "**Effective Date**") the Employee will step down from the Position and will be exempted from all of his duties and
responsibilities, and will become an advisory board member with the responsibilities as defined in Exhibit A. The Employee will make
himself available for any questions or assistance the Company may need, until the Termination Date. During the period as of the Effective
Date and until the Termination Date, the Employee will be allowed to be involved in other activities, paid or unpaid, in any capacity,
subject to the Employee's undertakings according to this Agreement, including but not limited to section ‎14 of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.  **<u>Communication of Termination</u>** : Following the Effective Date, the Parties will communicate
the Employee's termination of the Position to the Company's employees and/or clients and/or suppliers and any other relevant third parties
by releasing a mutually agreed notice, as follows: *" **Dror would like to explore new directions promoting his professional career, and therefore will move to a part time position as advisory board member*** ". In addition, the Company will file a report to
the SEC and/or the NASDAQ, as required by law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.  **<u>Adaptation Period</u>** : according to the Employment Agreement the Employee is entitled to 4 months'
notice period. The Company agreed to grant the Employee, on an *ex-* gratia basis, with a much longer adaptation period of 28 months,
starting February 1, 2023 and ending May 31, 2025 (the "**Adaptation Period** "). During the Adaptation Period the
Employee will continue to be employed by the Company and to be entitled to receive a <u>monthly</u> salary of NIS 42,137 (gross) (the **"Adjusted Salary**") and all other benefits according to his Employment Agreement, as shall be calculated and paid according
to the Adjusted Salary.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.  **<u>Grant of Shares</u>** : Subject to all legally required corporate approvals, on an *ex-* gratia
basis, the Company shall grant the Employee with 75,000 of the Company's ordinary shares, that shall vest on a quarterly basis, over a
period as of the grant date and until December 31, 2024 (the "**2023 Shares** ").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. All the payments the Employee shall receive during the Adaptation Period based on the Adjusted Salary
and the 2023 Shares in accordance with this Agreement shall be referred to, together as "**Termination Package** ".

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.  **<u>Termination Date</u>** : the employment relationship between the Partied shall terminate at the
end of the Adaptation Period on May 31, 2025 (the "**Termination Date** "). The period as of the Commencement Date and
until the Termination Date shall be referred to in this Agreement as "**Employment Period** ".

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.  **<u>Notice Period</u>** : according to the Employment Agreement the Employee is entitled to 4 months'
notice period. The Employee expressly and explicitly agrees and confirms that the Termination Package is significantly higher than the
payment he would have been entitled to receive for 4 months' notice period based on his regular salary. Hence, the Employee expressly
confirms that the Termination Package will be in lieu of the payment for notice period according the Employment Agreement, and he will
not be entitled to any additional payment for the notice period, other than the Termination Package.

The Employee confirms that he was presented with a detailed calculation, supporting the above declaration, comparing his legal and contractual entitlements to the Termination Package.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.  **<u>Accrued Vacation</u>** : At the end of January 2023, the Employee has 90.68 accrued annual
leave days. The Employee expressly and explicitly agrees that the Termination Package is significantly higher than the payment he would
have been entitled to receive for redemption of his accrued annual leave days based on his regular salary. Hence, the Employee expressly
confirms that the Termination Package will be <u>in lieu</u> of the redemption of any accrued vacation days as per law and Employment
Agreement. Accordingly, it is agreed that all of the Employee's accrued vacation days shall be deleted as of February 2023 and it
is also agreed that during the Adaptation Period the Employee will not accrue any annual leave.

The Employee confirms that he was presented with a detailed calculation, supporting the above declaration, comparing his legal and contractual entitlements to the Termination Package.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.  **<u>Final Settlement of Account</u>** : upon Termination Date, together with the monthly salary for
May 2025 and/or on the date required by law, a final settlement of account shall be carried out, and the Company shall pay to the
Employee the following sums and/or provide the Employee with the following documents:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.1. Payment of the Adjusted Salary through the Termination Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.2. Payment of any unpaid recuperation pay through the Termination Date, all subject to applicable law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.3. Provide the Employee with letters of release with respect to the amounts accrued under the Employee's
managers' insurance policy and/or pension fund (severance pay and pension component). Due to the application of the arrangement
under Section 14 of the Severance Pay Law, the Employee shall not be entitled to any other or additional payment with respect to
severance pay other than the release of the accrued severance, as stated in this section.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.4. Provide the Employee with 161 Form with respect to the released severance pay, as stated in section
 ‎9.3 above.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.5. Provide the Employee with letters of release with respect to the amounts accrued under the Employee's
education fund.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.6. Provide a letter of confirmation of the Employee's employment period.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.  **<u>Options and Capital Grants</u>** : all options and capital grants granted to the Employee during
the Employment Term, shall be governed by the terms and conditions of the Company's relevant option plan and the Employee's relevant
option agreements and/or grant letters. Any outstanding, but unvested options and capital grants shall expire upon and become of no force
and effect on the Termination Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.  **<u>Taxation</u>** : All payments and benefits related to the Employee's employment and its termination,
including those set forth herein, are gross payments, from which tax and other compulsory payments shall be deducted, as required by law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.  **<u>Ex-gratia Benefits</u>** : The Company's agreement to grant the Employee the ex-gratia benefits,
providing his with the Termination Package, as stated in this Agreement, is conditioned on the Employee's full and complete satisfaction
of all applicable obligations pursuant to any law and/or Employment Agreement and/or and this Agreement, without exception.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.  **<u>Return of Company's Property</u>** : Upon the Termination Date, the Employee will deliver to the
Company all of the Company's property in his possession, including but not limited to any documents, written materials, any electronic
devices (including laptop, PC, smartphone, tablet etc.) any cards provided by the Company to the Employee and any of the Company's keys.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.  **<u>Confidentiality and Unfair Competition</u>** : All undertakings applicable to the Employee pursuant
to law and the Employment Agreement, relating to confidentiality, intellectual property ownership and assignment, non-compete and non-solicitation,
shall remain in full force and effect and shall continue to oblige the Employee, all in accordance with the provisions of the Employment
Agreement. It was agreed between the Parties, that the unfair competition obligation of the Employee will apply as of the Effective Date
of this Agreement and for a period of 12 months thereafter..

The Employee declares and acknowledges that working for the following companies Livongo and/or Omada and/or Virta and/or Vida will be considered as a breach under this section and his Employment Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.  **<u>No Disparagement</u>** : Each party undertakes to maintain the dignity of the other party, not
to defame or to slander the other party, even if one party believes in the content. It is hereby clarified that statements by unauthorized
employees and managers of the Company, who are not qualified to bind the Company, will not be considered a violation by the Company of
the provisions of this Section.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16.  **<u>Waiver and Release</u>** : Subject to the timely payment/provision by the Company of all amounts/benefits
provided in this Agreement, specifically the Termination Package, the Employee irrevocably declares and warrants the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16.1. The Employee confirms that he has received from the Company all of the rights and the amounts which are
due to him in connection with the entire Employment Term and/or the termination of his employment, including salary, overtime, vacation
pay and/or vacation redemption pay, sick pay, recuperation pay, holiday pay, contributions to pension schemes, contributions to education
fund, premiums and bonuses of all kinds, travel expenses and/or car allowance, notice period pay and severance pay, personal injury or
any other claim for damages or injury of any kind whatsoever, stock or stock options or other capital grants, exercising options and any
other payment arising from the Employment Term and/or from the termination of employment, including with respect to the circumstances
of such termination, discrimination, wrongful dismissal and restrictions on layoffs (including the process of termination which the Employee
waived), to which he was or may have been entitled by virtue of any law and/or statute and/or Employment Agreement and/or Company's practice.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16.2. The Employee confirms that the payments, including all the ex-gratia Termination Package, as set forth
in this Agreement, constitute the final, agreed and absolute arrangement, which exhausts all of the claims, demands and lawsuits of the
Employee against the Company, and that he has no claims and shall have no claims, demands or lawsuits against the Company, and the Employee
undertakes to refrain from any legal proceeding against the Company with regard to claims and/or demands and/or lawsuits of any kind or
nature, contractual, tort or other, based on any grounds whatsoever, or in any manner whatsoever, which are known on the date of the signing
of the Agreement, and such which are not known, and which arise from any law or statute whatsoever.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16.3. The Employee hereby specifically waives any right, claim, or demand he may have, if any, with respect

property, including but not limited to any claim for consideration regarding Service Invention, under Article 134 of the Patents
Law, 1967 and claim or demand regarding the eligibility to receive royalties, compensation or rewards before the Compensation and Royalties
Committee set up at the Office of the Patents Registrar.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16.4. The Employee confirms that this Agreement and the Termination Package shall also constitute a "package
deal" and a settlement and release agreement as construed in Section 29 of the Severance Pay Law, 1963 and the Employee shall
have not additional demands with respect to the severance pay.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;17.  **<u>Breach and Remedies</u>** : Without derogating from any remedy available to Company under applicable
law, in any event of a breach of any of Employee's undertakings pursuant to this Agreement, the Employee hereby: (1) undertakes to
return to the Company the amount of all of the ex-gratia benefits or the value thereof and (2) agrees that the Company may set off
any sum outstanding under this section against any sum that may be awarded to the Employee in any legal proceedings.

In the event that the Employee's employment with the Company will be terminated by the Company prior to the Termination Date, for any reason **<u>other than</u>** breach of this Agreement by the Employee (the "**Early Termination**"), then the Company will be obligated to pay the Employee all and any outstanding amounts due to him under this Agreement, in one lump sum, upon such Early Termination.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18.  **<u>Corporate Approvals</u>** : This Agreement is subject to all statutory and legally required corporate
approvals, including but not limited to board of directors of the Company and compensation committee of the Company, and such approvals,
should they be required by law, shall be a condition precedent to this agreement being valid and in effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19.  **<u>General Provisions</u>** :

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19.1. This Agreement constitutes the entire agreement between the Parties in connection with the terms of the
Employee's termination of employment with the Company and all prior negotiations, agreements and understandings, written or oral,
between the Parties with respect to Employee's termination prior to this Agreement shall be of no force or effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19.2. No amendment and/or modification of this Agreement shall have any effect unless such amendment or modification
shall be done in a written document, signed by both Parties.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19.3. Nothing in this Agreement shall derogate from any of the Employee's obligations according to the
Employment Agreement and the applicable law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19.4. The Employee's declarations and undertakings towards the Company under this Agreement shall also
apply, *mutatis mutandis*, to any entity related to the Company by way of a relationship of a parent company, sister company, and
so on and so forth, and its employees and/or directors and/or its authorized representatives and/or acting on its behalf, including all
the officers of such entities, all jointly and/or severally.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19.5. Both Parties have executed this Agreement voluntarily, without any duress or undue influence on the part
or behalf of the other party, after being provided with the right to consult with legal counsel, after understanding the content of this
Agreement and considering the implications thereof, including the release contained thereunder.

**IN WITNESS WHEREOF**, the Parties have executed this Agreement:

---

| | |
|:---|:---|
| &nbsp;&nbsp;/s/ Erez Raphael | &nbsp;&nbsp;/s/ Dror Bacher |
| &nbsp;&nbsp;**Labstyle Innovation Ltd.** | &nbsp;&nbsp;**Dror Bacher** |
| &nbsp;&nbsp;23/01/2023 | &nbsp;&nbsp;23/01/2023 |
| &nbsp;&nbsp;**Date** | &nbsp;&nbsp;**Date** |

---